Condensed Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities:
Net income (loss)	$ 150,746	$ (355,181)
Adjustments to reconcile net income (loss) net cash used in operating activities:
Depreciation expense	4,400	5,236
Amortization of patents	19,375	18,921
Amortization of debt discount	0	1,532
Common stock and options for compensation, consulting and vendor services	280,610	41,439
Accrued interest expense on notes payable	24,419	20,839
Bad debt reversal	(55,987)	(42,326)
Loss on Earning on Medical Joint Venture		78,095
Changes in operating assets and liabilities:
(Increase) Decrease in accounts receivable	(246,594)	157,927
Decrease in inventories	13,012	201,321
Decrease to advance to contracts	39,756	108,081
Decrease to prepaid expenses and other current assets	73,119	6,949
Decrease in other assets		7,503
Decrease in accounts payable	(306,322)	(524,525)
(Decrease) Increase in accrued expenses	(80,201)	151,001
Net cash used in operating activities	(83,667)	(123,188)
Cash flows from investing activities:
Investment in Education Joint Venture	(50,000)
Purchases of property and equipment	(856)
Payment for patents rights	(9,122)	(10,150)
Net cash used in investing activities	(59,978)	(10,150)
Cash flows from financing activities:
Proceeds from the sale of common stock	50,000	150,000
Proceeds from loan from related party	50,000
Net cash provided by financing activities	100,000	150,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(43,645)	16,662
Cash and cash equivalents at beginning of period	165,249	96,324
Cash and cash equivalents at end of period	121,604	112,986
Supplemental disclosure of cash flow information:
Shares issued to employees in lieu of cash compensation	$ 11,875	$ 7,500